Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
EBBH-2024 by Essen Biotech for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Data Insights
EBBH-2024 by Essen Biotech for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...